BNTX FDA calendar & decision history Merck · 1 upcoming · 1 past FDA decision
Upcoming FDA catalysts BNTX · Aug 17, 2026 KEYTRUDA (pembrolizumab) + Padcev — Perioperative muscle-invasive bladder cancer (sBLA) FDA decision history (1) Aug 27, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates BNTX's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio